BP11134 PLGA 65:35, Carboxyl-Terminated, IV: 0.45–0.55 dl/g, Mw: 53–70 kDa

PLGA 65:35, Carboxyl-Terminated, IV: 0.45–0.55 dl/g, Mw: 53–70 kDa Description

PLGA 65:35, Carboxyl-Terminated, IV: 0.45–0.55 dl/g, Mw: 53–70 kDa is a copolymer consisting of 65% lactic acid and 35% glycolic acid with terminal carboxyl groups that promote hydrolytic degradation. The specified intrinsic viscosity corresponds to polymer chain length, ensuring controllable resorption rates essential for biomedical applications. Its powdered form simplifies formulation, processing, and consistent performance across various research and clinical settings.

PLGA 65:35, Carboxyl-Terminated, IV: 0.45–0.55 dl/g, Mw: 53–70 kDa Applications

1.         Biomedical Applications
   - Used as a matrix in controlled drug delivery systems to achieve sustained release by utilising its predictable degradation profile.
   - Applied as a scaffold in tissue engineering constructs to promote cell attachment and gradual absorption due to its defined carboxyl termination.

2.         Research Applications
   - Employed in preclinical studies to evaluate degradation kinetics and biocompatibility, benefiting from its specified molecular weight range and compositional consistency.

PLGA 65:35, Carboxyl-Terminated, IV: 0.45–0.55 dl/g, Mw: 53–70 kDa Packing

The product is packaged in moisture-resistant, anti-static containers to minimise environmental exposure and contamination. Sealed and clearly labelled, the packaging preserves the powdered state and prevents agglomeration during transport and storage. Storage in a cool, dry environment is recommended to maintain material integrity. Custom packaging options are available to accommodate specific storage and handling requirements.

Additional Information

Biocompatible polymers such as PLGA serve a critical role in biomedical fields due to their controlled degradation properties. The balance between lactic and glycolic acid components directly influences both mechanical performance and resorption rates, making these materials suitable for drug delivery and tissue engineering applications.

Advanced analytical techniques, including gel permeation chromatography and Fourier-transform infrared spectroscopy, are integral to characterising and ensuring the consistency of PLGA materials. These methods support quality control and facilitate the development of reproducible processes for both research and clinical applications.

Regulatory Note: This material is intended for industrial and research applications. It is the customer's responsibility to ensure compliance with all relevant safety and regulatory standards in their intended use.